---
title: 'No benefit from TMZ treatment in GB with truly unmethylated MGMT promoter:
  Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly GB patients'
date: '2024-06-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38912869/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240624182446&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: For evidence-based treatment of glioblastoma patients validated
  MGMTp methylation assays should be used that accurately identify truly unmethylated
  patients. Respective stratified management of patients will reduce toxicity without
  compromising outcome and allow testing of more promising treatment ...'
disable_comments: true
---
CONCLUSION: For evidence-based treatment of glioblastoma patients validated MGMTp methylation assays should be used that accurately identify truly unmethylated patients. Respective stratified management of patients will reduce toxicity without compromising outcome and allow testing of more promising treatment ...